These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 38168866)
21. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists. Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746 [TBL] [Abstract][Full Text] [Related]
22. The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH. Sountoulides P; Gravas S Curr Drug Targets; 2015; 16(11):1172-9. PubMed ID: 25706255 [TBL] [Abstract][Full Text] [Related]
23. Enhanced prostatic Esr1 Sharkey C; Long X; Al-Faouri R; Strand D; Olumi AF; Wang Z J Pathol; 2024 Jul; 263(3):300-314. PubMed ID: 38606616 [TBL] [Abstract][Full Text] [Related]
24. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia. De Nunzio C; Presicce F; Tubaro A Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117 [TBL] [Abstract][Full Text] [Related]
25. Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. Lin-Tsai O; Clark PE; Miller NL; Fowke JH; Hameed O; Hayward SW; Strand DW Prostate; 2014 May; 74(6):669-79. PubMed ID: 24500928 [TBL] [Abstract][Full Text] [Related]
27. Comparison of Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Treated with Finasteride and Alpha Blocker Combination Therapy Versus Alpha Blocker Monotherapy in China: An Analysis of Electronic Medical Record Data. Fu Y; Han S; Wang L; Gao W; Wu E; Cao X; Wang J Adv Ther; 2018 Aug; 35(8):1191-1198. PubMed ID: 30014350 [TBL] [Abstract][Full Text] [Related]
28. Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia. Chang LW; Wang SS; Yang CK; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Li JR Anticancer Res; 2023 Jan; 43(1):485-491. PubMed ID: 36585197 [TBL] [Abstract][Full Text] [Related]
29. Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia. Joo KJ; Sung WS; Park SH; Yang WJ; Kim TH J Int Med Res; 2012; 40(3):899-908. PubMed ID: 22906262 [TBL] [Abstract][Full Text] [Related]
30. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States. DerSarkissian M; Xiao Y; Duh MS; Lefebvre P; Swensen AR; Bell CF J Manag Care Spec Pharm; 2016 Oct; 22(10):1204-14. PubMed ID: 27668569 [TBL] [Abstract][Full Text] [Related]
31. Benign prostatic hyperplasia nodules in patients treated with celecoxib and/or finasteride have reduced levels of NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, a mitochondrial protein essential for efficient function of the electron transport chain. Liu TT; Igarashi T; El-Khoury N; Ihejirika N; Paxton K; Jaumotte J; Dhir R; Hudson CN; Nelson JB; DeFranco DB; Yoshimura N; Wang Z; Pascal LE Prostate; 2024 Oct; 84(14):1309-1319. PubMed ID: 39004950 [TBL] [Abstract][Full Text] [Related]
32. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study. Alcaraz A; Carballido-Rodríguez J; Unda-Urzaiz M; Medina-López R; Ruiz-Cerdá JL; Rodríguez-Rubio F; García-Rojo D; Brenes-Bermúdez FJ; Cózar-Olmo JM; Baena-González V; Manasanch J Int Urol Nephrol; 2016 May; 48(5):645-56. PubMed ID: 26810324 [TBL] [Abstract][Full Text] [Related]
33. The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality. Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Horwitz RI; Jacobsen SJ Urology; 2018 Sep; 119():70-78. PubMed ID: 29906480 [TBL] [Abstract][Full Text] [Related]
34. [Benign prostate hyperplasia: success and limitations of pharmacological therapy]. Madersbacher S; Marszalek M Internist (Berl); 2007 Oct; 48(10):1157-64. PubMed ID: 17426942 [TBL] [Abstract][Full Text] [Related]
35. The role of combination medical therapy in benign prostatic hyperplasia. Greco KA; McVary KT Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123 [TBL] [Abstract][Full Text] [Related]
36. Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia. Krishnamoorthi R; Ganapathy A A; Hari Priya VM; Kumaran A J Ethnopharmacol; 2024 Aug; 330():118207. PubMed ID: 38636573 [TBL] [Abstract][Full Text] [Related]
39. NF-κB and androgen receptor variant expression correlate with human BPH progression. Austin DC; Strand DW; Love HL; Franco OE; Jang A; Grabowska MM; Miller NL; Hameed O; Clark PE; Fowke JH; Matusik RJ; Jin RJ; Hayward SW Prostate; 2016 Apr; 76(5):491-511. PubMed ID: 26709083 [TBL] [Abstract][Full Text] [Related]
40. Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia? McVary KT; Rogers T; Mahon J; Gupta NK J Sex Med; 2018 Dec; 15(12):1728-1738. PubMed ID: 30446471 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]